Objectives: To compare European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI broth microdilution (BMD) methods for testing the novel antifungal E1210 against a recent collection of 102 clinical isolates of Candida spp.
Introduction
Despite the introduction of extended-spectrum triazoles and the echinocandin class of antifungal agents, there remains a need for additional agents with novel mechanisms of action in order to combat the steady emergence of antifungal resistance among the various species of Candida.
1,2 E1210 (Eisai Co., Japan) is a first-in-class broad-spectrum antifungal agent that suppresses hyphal growth by inhibiting fungal glycosylphosphatidylinositol (GPI) biosynthesis. 3 -5 Preliminary data using the CLSI broth microdilution (BMD) method 6 has demonstrated the excellent potency and spectrum of E1210 against Candida spp.; however, specific methodological parameters such as the duration of incubation, MIC endpoint determination and the level of agreement between the CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) BMD methods must be investigated. 6 -8 Currently there are two independent standards for BMD susceptibility testing of antifungal agents against Candida species; the CLSI method 6 and the EUCAST method. 8 The two methods are similar in that both use BMD, RPMI 1640 broth, 35 -378C incubation temperatures and a prominent inhibition (50% relative to the growth control) MIC endpoint for both the triazoles and echinocandins. 9 -11 similar data are not available for E1210. Given the important role that both methods currently play in antifungal developmental resistance surveillance, it is important to demonstrate the comparability of the results in the pre-clinical studies of new antifungal agents. In the present study we used a panel of Candida spp. isolates, selected to represent phenotypically and genotypically antifungal-resistant strains, to first examine the effect of incubation time and MIC endpoint criterion on the results of the CLSI method and subsequently to determine the essential agreement (EA; MIC +2 log 2 dilutions) between CLSI and EUCAST BMD results using the optimized CLSI conditions. Prior to testing, each isolate was passaged at least twice onto Sabouraud dextrose agar (Remel, Lenexa, KS, USA) and CHROMagar Candida medium (Becton Dickinson, Sparks, MD, USA) to ensure purity and viability.
Materials and methods
All isolates were tested for in vitro susceptibility to E1210 using the CLSI and EUCAST BMD methods. 6 -8 Reference powder of E1210 was obtained from the manufacturer. Stock solutions were prepared in DMSO and the final range of E1210 concentrations tested was 0.008-16 mg/L. CLSI BMD testing was performed exactly as outlined in document M27-A3 6 by using RPMI 1640 medium with 0.2% glucose, inocula of 0.5×10 3 to 2.5×10 3 cells/mL and incubation at 358C. MIC values were determined visually after both 24 and 48 h of incubation. MIC endpoint criteria at both reading times included the lowest concentration of drug that caused a significant diminution (≥50% inhibition) as well as complete (100%) inhibition of growth relative to that of the growth control.
EUCAST BMD testing was performed exactly as outlined in document EDef. 7.1 8 by using RPMI 1640 medium with 2.0% glucose, inocula of 0.5×10 5 to 2.5×10 5 cells/mL and incubation at 358C. MIC values were determined spectrophotometrically (at 530 nm), after 24 h of incubation, as the lowest concentration of drug that resulted in both ≥50% inhibition and 100% inhibition of growth relative to that of the growth control. Quality control (QC) was ensured by testing the following strains recommended by CLSI 6 and EUCAST; 8 C. krusei ATCC 6258 and C. parapsilosis ATCC 22019. Fluconazole was included in each MIC panel for QC purposes. All fluconazole results were within the acceptable QC limits. The MIC results for E1210 obtained with the CLSI method using both partial (≥50%) and complete (100%) inhibition were compared at each reading time in order to determine the EA between MIC values obtained at 24 and 48 h with each endpoint criterion and subsequently to determine the EA at 24 h between MIC values determined using partial versus complete endpoint criteria. The MIC results for E1210 obtained with the EUCAST method were compared with those of the CLSI method at 24 h of incubation using both complete and partial inhibition criteria for both methods. High off-scale MIC results were converted to the next highest concentration and low off-scale MIC results were left unchanged. Discrepancies of .+2 log 2 dilutions among MIC results were used to calculate the EA. Pfaller et al.
Results and discussion
active against C. krusei (MIC 50 ≥16 mg/L; data not shown). The MIC results determined by the CLSI method ranged from ≤0.008 to 1 mg/L depending on the species, duration of incubation and MIC endpoint criteria. Overall, the EA between the 24 and 48 h CLSI readings was 100.0% (76% within +1 dilution) using the partial inhibition (≥50%) endpoint criterion and 97.6% (91% within +1 dilution) using the complete (100%) inhibition endpoint criterion. Given that the 24 and 48 h MIC readings were comparable, and assuming that an earlier MIC reading is preferable to a later reading, we determined the EA between MIC results read at 24 h of incubation using the two different endpoint criteria. Comparison of the MIC results obtained with the CLSI method at 24 h of incubation and using the two different MIC endpoints showed an overall EA of 100% (83% within +1 dilution).
Comparison of CLSI and EUCAST methods read at 24 h of incubation and either partial or complete inhibition revealed an EA of 97.8% using the partial inhibition endpoint criterion and 88.9% using the complete inhibition endpoint criterion (Table 2) . Among the few discrepancies noted, the CLSI method tended to produce higher values using the partial inhibition criterion, whereas the EUCAST method tended to give higher values using the complete inhibition endpoint criterion.
The results of this pre-clinical methods assessment of the in vitro activity of E1210 against Candida spp. indicate that the drug may be tested using either the CLSI or EUCAST BMD method and an incubation time of 24 h. Although either partial and complete inhibition MIC endpoints give comparable results, the highest level of inter-and intra-method agreement was observed when the partial inhibition (≥50%) endpoint was used for both methods.
In summary, E1210 has potent in vitro activity against Candida spp. when tested by both reference BMD methods. 6 -8 Optimal testing conditions using CLSI and EUCAST methods include 24 h of incubation and a ≥50% inhibition MIC endpoint criterion. When these conditions are employed one may achieve a high level of inter-method agreement for testing E1210 versus Candida. 
